(-)-PHCCC, a positive allosteric modulator of mGluR4: Characterization, mechanism of action, and neuroprotection

Neuropharmacology

Volumn 45, Issue 7, 2003, Pages 895-906

  Maj, M ^a   Bruno, V ^a   Dragic, Z ^a   Yamamoto, R ^a   Battaglia, G ^b   Inderbitzin, W ^a   Stoehr, N ^a   Stein, T ^a   Gasparini, F ^a   Vranesic, I ^a   Kuhn, R ^a   Nicoletti, F ^b,c   Flor, P J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b IRCCS NEUROMED   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Excitotoxicity; Metabotropic glutamate receptors; Neuroprotection; Positive modulation; amyloid toxicity

Indexed keywords

2 AMINO 4 PHOSPHONOBUTYRIC ACID; 6,7 DINITRO 2,3 QUINOXALINEDIONE; AMYLOID BETA PROTEIN; DIZOCILPINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID; N PHENYL 7 (HYDROXYIMINO)CYCLOPROPA[B]CHROMEN 1A CARBOXAMIDE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BRAIN CELL; CHIMERA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; ENANTIOMER; FETUS; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 0142090782     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00271-5     Document Type: Article

References (57)

1. Annoura H., Fukunaga A., Uesugi M., Tatsuoka T., Horikawa Y. A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino) cyclopropa[b]chromen-1a-carboxylates. Bioorg Med Chem Letters. 6:1996;763-766.
2. Battaglia G., Bruno V., Pisani A., Centonze D., Catania M.V., Calabresi P., Nicoletti F. Selective blockade of type-I metabotropic glutamate receptors induces neuroprotection by enhancing GABAergic transmission. Mol Cell Neurosci. 17:2001;1071-1083.
3. Baez M., Yang P., Kandasamy R., Large T., Kelly G., Christensen K., Johnson M.P. Molecular mapping of a subtype selective site for positive allosteric modulation of the mGlu2 receptor. Neuropharmacology. 43:2002;274-275. Abstract 8.
4. Besong G., Battaglia G., D'Onofrio M., Di Marco R., Ngomba R.T., Storto M., Castiglione M., Mangano K., Busceti C.L., Nicoletti F.R., Bacon K., Tusche M., Valenti O., Conn P.J., Bruno V., Nicoletti F. Activation of group-III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. J Neurosci. 22:2002;5403-5411.
5. Britton T., Barda D., Hornback W., Jagdmann G.E., Henry S., Fichtner M., Wang Z.-Q., Coleman D., Chenoweth D., Vaught G., Fivush A., Dressman B., White R., Milot G., Herr R.J., Burry L., Johnson M., Large T., Monn J., Schoepp D.D. Selective, non-amino-acid allosteric potentiators of mGlu2 receptors. Neuropharmacology. 43:2002;279.
6. Bruno V., Copani A., Bonanno L., Knöpfel T., Kuhn R., Roberts P.J., Nicoletti F. Activation of group-III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur J Pharmacol. 310:1996;61-66.
7. Bruno V., Sureda F.X., Storto M., Casabona G., Caruso A., Knöpfel T., Kuhn R., Nicoletti F. The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signalling. J Neurosci. 17:1997;1891-1897.
8. Bruno V., Battaglia G., Casabona G., Copani A., Caciagli F., Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-β J Neurosci. 18:1998;9594-9600.
9. Bruno V., Battaglia G., Kingston A., O'Neill J.M., Catania M.V., Di Grezia R., Nicoletti F. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4- carboxyphenilglycine (LY367385): comparison with LY367366, an antagonist of mGlu1a and mGlu5 receptors. Neuropharmacology. 38:1999;199-207.
10. Bruno V., Battaglia G., Ksiazek I., van der Putten H., Catania M.V., Giuffrida R., Lukic S., Leonhardt T., Inderbitzin W., Gasparini F., Kuhn R., Hampson D.R., Nicoletti F., Flor P.J. Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J Neurosci. 20:2000;6413-6420.
11. Bruno V., Battaglia G., Copani A., D'Onofrio M., Di Iorio P., De Blasi A., Melchiorri D., Flor P.J., Nicoletti F. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cerebral Blood Flow and Metabolism. 21:2001;1013-1033.
12. Copani A., Bruno V., Battaglia G., Leanza G., Pellitteri R., Russo A., Stanzani S., Nicoletti F. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol Pharmacol. 47:1995;890-897.
13. D'Onofrio M., Cuomo L., Battaglia G., Ngomba T.R., Storto M., Kingston A.E., Orzi F., De Blasi A., Nicoletti F., Bruno V. Neuroprotection mediated by group-II metabotropic glutamate receptors involves the activation of the MAP kinase pathway and requires the induction of TGF-β1. J Neurochem. 78:2001;435-445.
14. De Blasi A., Conn P.J., Pin J.-P., Nicoletti F. Molecular determinants of metabotropic glutamate receptor signaling. Trends in Pharmacol Sci. 22:2001;114-120.
15. D'Mello S.R., Borodezt K., Soltoff S.P. Insulin-like growth factor and potassium depolarization maintain neuronal survival by distinct pathways: possible involvement of PI 3-kinase in IGF-1 signaling. J Neurosci. 17:1997;1548-1560.
16. Flor P.J., Lukic S., Rüegg D., Leonhardt T., Knöpfel T., Kuhn R. Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 4. Neuropharmacology. 34:1995;149-155.
17. Flor P.J., Gomeza J., Tones M.A., Kuhn R., Pin J.P., Knöpfel T. The C-terminal domain of the mGluR1 metabotropic glutamate receptor affects sensitivity to agonists. J Neurochem. 67:1996;58-63.
18. Flor P.J., Van Der Putten H., Rüegg D., Lukic S., Leonhardt T., Bence M., Sansig G., Knöpfel T., Kuhn R. A novel splice variant of a metabotropic glutamate receptor, human mGluR7b. Neuropharmacology. 36:1997;153-159.
19. Flor P.J., Battaglia G., Nicoletti F., Gasparini F., Bruno V. Neuroprotective activity of metabotropic glutamate receptor ligands. Adv Exp Med Biol. 513:2002;197-223.
20. Gasparini F., Bruno V., Battaglia G., Lukic S., Leonhardt T., Inderbitzin W., Laurie D., Sommer B., Varney M.A., Hess S.D., Johnson E.C., Kuhn R., Urwyler S., Sauer D., Portet C., Schmutz M., Nicoletti F., Flor P.J. (R,S)-4-phosphonophenylglycine, a potent and selective group-III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther. 289:1999;1678-1687.
21. Gasparini F., Lingenhöhl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeirer H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Veliçelebi G., Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 38:1999;1493-1503.
22. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 260:1985;3440-3450.
23. Hall D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation. Mol Pharmacol. 58:2000;1412-1423.
24. Henrich-Noack P., Flor P.J., Sabelhaus C.F., Prass K., Dirnagl U., Gasparini F., Sauter A., Rudin M., Reymann K.G. Distinct influence of the group-III metabotropic glutamate receptor agonist (R,S)-4- phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage. Neuropharmacology. 39:2000;911-917.
25. Iacovelli L., Bruno V., Salvatore L., Melchiorri D., Gradini R., Caricasole A., Barletta E., De Blasi A., Nicoletti F. Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways. J Neurochem. 82:2002;216-223.
26. Johnson M., Baez M., Britton T., Jagdman G.E. Jr., Jonhson K., Jonhson B., Hornback W., Large T., Nisenbaum E., Tizzano J., Monn J., Schoepp D. Subtype-selective positive allosteric modulators of the metabotropic glutamate 2 receptor: in vitro and in vivo characterization of novel mGlu2 potentiators. Neuropharmacology. 43:2002;291.
27. Kingston A.E., O'Neill M.J., Lam A., Bales K.R., Monn J.A., Schoepp D.D. Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795. Eur J Pharmacol. 377:1999;155-165.
28. Knoflach F., Mutel V., Jolidon S., Kew J.N., Malherbe P., Vieira E., Wichmann J., Kemp J.A. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci. 98:2001;13402-13407.
29. Knöpfel T., Sakaki J., Flor P.J., Baumann P., Sacaan A.I., Velicelebi G., Kuhn R., Allgeier H. Profiling of trans-azetidine-2,4- dicarboxylic acid at the human metabotropic glutamate receptors mGlu1b, -2, -4a and -5a. Eur J Pharmacol. 288:1995;389-392.
30. 35S]GTPgammaS binding assessment of metabotropic glutamate receptor standards in Chinese hamster ovary cell lines expressing the human metabotropic receptor subtypes 2 and 4. Neuropharmacology. 37:1998;179-187.
31. Lafon-Cazal M., Fagni L., Guiraud M.J., Mary S., Lerner-Natoli M., Pin J.-P., Shigemoto R., Bockaert J. mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons. Eur J Neurosci. 11:1999;663-672.
32. 35S]-GTP gamma S binding mediated by human muscarinic m1-m4 receptors: antagonist studies. British J Pharmacol. 109:1993;1120-1127.
33. Lie A.A., Becker A., Behle K., Beck H., Malitschek B., Conn P.J., Kuhn R., Nitsch R., Plaschke M., Schramm J., Elger C.E., Wiestler O.D., Blumcke I. Up-regulation of the metabotropic glutamate receptor mGluR4 in hippocampal neurons with reduced seizure vulnerability. Annali of Neurology. 47:2000;26-35.
34. Litschig S., Gasparini F., Ruegg D., Stoehr N., Flor P.J., Vranesic I., Prezeau L., Pin J.-P., Thomsen C., Kuhn R. CPCCOEt, a non-competitive mGluR1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol. 55:1999;453-461.
35. Mathiesen J.N., Svendsen N., Bräuner-Osborne H., Thomsen C., Ramirez M.T. Positive allosteric modulation of the human metabotropic glutamate receptor (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol. 138:2003;1026-1030.
36. Maiese K., Greenberg R., Boccone L., Swiriduk M. Activation of the metabotropic glutamate receptor is neuroprotective during nitric oxide toxicity in primary hippocampal neurons of rats. Neurosci Lett. 194:1995;173-176.
37. Maiese K., Vincent A., Lin S.H., Shaw T. Group-I and group-III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. J Neurosci Res. 62:2000;257-272.
38. Martin G., Nie Z., Siggins G.R. Metabotropic glutamate receptors regulate N-methyl-D-aspartate-mediated synaptic transmission in nucleus accumbens. J Neurophys. 78:1997;3028-3038.
39. +-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem. 76:2001;351-360.
40. Nawy S., Jahr C.E. Suppression by glutamate of cGMP-activated conductance in retinal bipolar cells. Nature. 346:1990;269-271.
41. Orlando L.R., Alsdorf S.A., Penney J.B. Jr., Young A.B. The role of group-I and group-II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity. Exp Neurol. 167:2001;196-204.
42. Pagano A., Ruegg D., Litschig S., Stoehr N., Stierlin C., Heinrich M., Floersheim P., Prezeau L., Carroll F., Pin J.-P., Cambria A., Vranesic I., Flor P.J., Gasparini F., Kuhn R. The non-competitive antagonists 2-methyl-6- (phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group-I metabotropic glutamate receptors. J Biol Chem. 275:2000;33750-33758.
43. Parmentier M.L., Prezeau L., Bockaert J., Pin J.-P. A model for the functioning of family 3 GPCRs. TIPS. 23:2002;268-274.
44. Pellegrini-Giampietro D.E., Cozzi A., Peruginelli F., Leonardi P., Meli E., Pellicciari R., Moroni F. 1-Aminoindan-1,5-dicarboxylic acid and (S)-(+)-2-(3'-carboxyicyclo(1.1.1.)pentyl)-glycine, two mGlu1 receptor-preferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischemia. Eur J Neurosci. 11:1999;3637-3647.
45. Pellegrini-Giampietro D.E., Peruginelli F., Meli E., Cozzi A., Albani-Torregrossa S., Pellicciari R., Moroni F. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms. Neuropharmacology. 38:1999;1607-1619.
46. Pin J.-P., De Colle C., Bessis A.S., Acher F. New perspectives for the development of selective metabotropic glutamate receptor ligands. Eur J Pharmacol. 375:1999;277-294.
47. Rose K., Goldberg M.P., Choi D.W. Cytotoxicity in murine neocortical cell cultures. Tyson C.A., Frazier J.M. Methods in toxicology, Vol. 1, In vitro biological system. 1992;46-60 San Diego Academics, San Diego.
48. Sabelhaus C.F., Schroder U.H., Breder J., Henrich-Noack P., Reymann K.G. Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group-III metabotropic glutamate receptor agonist (R, S)-4- phosphonophenylglycine. British J Pharmacol. 131:2000;655-658.
49. Shigemoto R., Kinoshita A., Wada E., Nomura S., Ohishi H., Takada M., Flor P.J., Neki A., Abe T., Nakanishi S., Mizuno N. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci. 17:1997;7503-7522.
50. Strasser U., Lobner D., Berhens M.M., Canzoniero L.M., Choi D.W. Antagonists of group-I mGluRs attenuate exicitotoxic neuronal death in cortical cultures. Eur J Neurosci. 10:1998;2848-2855.
51. Thomas N.K., Jane D.E., Tse H.W., Watkins J.C. alpha-Methyl derivatives of serine-O-phosphate as novel, selective competitive metabotropic glutamate receptor antagonists. Neuropharmacology. 35:1996;637-642.
52. Thomsen C., Kristensen P., Mulvihill E., Haldeman B., Suzdak P.D. L-2-amino-4-phosphonobutyrate (L-AP4) is an agonist at the type IV metabotropic glutamate receptor which is negatively coupled to adenylate cyclase. Eur J Pharmacol. 227:1992;361-362.
53. Tones M.A., Bendali N., Flor P.J., Knöpfel T., Kuhn R. The agonist selectivity of a class III metabotropic glutamate receptor, human mGluR4a, is determined by the N-terminal extracellular domain. Neuroreport. 7:1995;117-120.
54. Urwyler S., Mosbacher J., Lingenhoehl K., Heid J., Hofstetter K., Froestl W., Bettler B., Kaupmann K. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3- hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol. 60:2001;963-971.
55. Varney M.A., Cosford N., Jachec C., Rao S.P., Sacaan A., Lin F.F., Bleicher L., Santori E.M., Flor P.J., Allgeier H., Gasparini F., Kuhn R., Hess S.D., Veliçelebi G., Jonhson C. SIB-1757 and SIB-1893: selective, non-competitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther. 290:1999;170-181.
56. Venero J.L., Santiago M., Tomas-Camardiel M., Matarredona E.R., Cano J., Machado A. DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury. Neurosci. 113:2002;857-869.
57. Wong C.G., Scherer S.W., Snead O.C., Hampson D.R. Localization of the human mGluR4 gene within an epilepsy susceptibility locus (1). Brain Res Mol Brain Res. 87:2001;109-116.